Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $47.6 million.

  • Akebia Therapeutics' Non-Current Debt rose 2421.07% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 2421.07%. This contributed to the annual value of $38.7 million for FY2024, which is 12518.19% up from last year.
  • Akebia Therapeutics' Non-Current Debt amounted to $47.6 million in Q3 2025, which was up 2421.07% from $47.1 million recorded in Q2 2025.
  • Akebia Therapeutics' Non-Current Debt's 5-year high stood at $97.2 million during Q3 2021, with a 5-year trough of $17.2 million in Q4 2023.
  • For the 5-year period, Akebia Therapeutics' Non-Current Debt averaged around $47.2 million, with its median value being $38.4 million (2024).
  • In the last 5 years, Akebia Therapeutics' Non-Current Debt crashed by 4957.74% in 2023 and then skyrocketed by 12518.19% in 2024.
  • Akebia Therapeutics' Non-Current Debt (Quarter) stood at $97.2 million in 2021, then tumbled by 64.95% to $34.1 million in 2022, then plummeted by 49.58% to $17.2 million in 2023, then soared by 125.18% to $38.7 million in 2024, then rose by 23.13% to $47.6 million in 2025.
  • Its Non-Current Debt was $47.6 million in Q3 2025, compared to $47.1 million in Q2 2025 and $46.5 million in Q1 2025.